Nicotine Science and Policy
By Harry Shapiro Aug. 13, 2026
Harry's blog 134: Filtering out lies and misinformation
The only major global journal focused on harm reduction has gone bust. Since 2017, Filter has advocated through journalism for rational and compassionate approaches to drug use, drug policy and human rights, while also standing out for its coverage of tobacco harm reduction. Its closure is a significant loss - particularly at a time when well-funded opponents of tobacco harm reduction continue to thrive.
October 09, 2026 by regulatorwatch.com
Rule Reset | FDA Signals Major Overhaul of PMTA Process | RegWatch
A reset of the FDA’s PMTA process is overdue if regulation is meant to guide the market rather than paralyse it. The current pathway has left many smoke-free products trapped in uncertainty while cigarettes remain legally available and illicit alternatives gain space. A better system should be rigorous, transparent and fast enough to distinguish responsible products from those that do not meet standards. Harm reduction depends on regulation that can make timely decisions, not one that delays safer options out of reach.
14.10% of the adult population are current smokers. There are approximately 39.8 million current smokers in United States 17.10% of men are current smokers but only 11.10% of women.
SOURCE: GSTHR
October 09, 2026 by planetofthevapes.co.uk
New Briefing Paper from GSTHR
The new GSTHR briefing paper focuses on a shift that is already happening: people moving from cigarettes to safer nicotine products. These transitions are not theoretical policy models; they can be seen across countries where vapes, pouches, snus and heated tobacco products are changing patterns of nicotine use. That matters because the public health gain comes from reducing exposure to combustion, even when nicotine use continues. Regulation should understand these pathways before it disrupts them.
September 29, 2026 by gsthr.org
For many people, the route away from smoking is not one clean break but a transition. The latest GS…
October 09, 2026 by pearlsandirritations.com
The growing gap between Australia’s policies on nicotine and reality
Australia’s nicotine policy is drifting further from the reality consumers are living in. Cigarettes remain legal, illicit tobacco is expanding, and many vapers are navigating workarounds, informal supply or rules that do not match how people actually quit smoking. That gap matters because policy cannot reduce harm effectively while pretending demand has disappeared or that restriction equals control. A better approach would start from real behaviour: keep people inside legal channels, make safer alternatives accessible, and measure success by fewer people smoking.
October 09, 2026 by clearingtheair.eu
A European House Divided
Europe’s nicotine debate is becoming a house divided. Some countries are moving towards risk-proportionate regulation, while others are pushing bans, higher taxes and restrictions that may leave cigarettes in a stronger position. That split matters because smokers across Europe are not facing the same chances to move away from combustion. A coherent EU strategy should protect young people, recognise product differences and make the lower-risk route easier to take than the deadly one.
October 08, 2026 by github.io
Eight Ministers Want to Freeze Europe's Smoke-Free Future
The EU’s direction on nicotine bans should be judged by what it leaves behind. Removing smoke-free …
October 08, 2026 by youtube.com
What are nicotine pouches?
What is inside a nicotine pouch matters because consumers deserve to understand the products they use. Beyond nicotine, pouches typically contain plant-based fibres, pH adjusters, flavourings, sweeteners and stabilisers that affect how the product feels, tastes and delivers nicotine. That does not make them risk-free, but it does make them very different from cigarettes, where burning tobacco creates thousands of toxic chemicals. Better public health communication should explain product contents clearly, rather than leaving nicotine pouches to be judged by suspicion alone.
- Page 1 of 46
Blogs
Harry's blog 134: Filtering out lies and misinformation
The only major global journal focused on harm reduction has gone bust. Since 2017, Filter has advocated through journalism for rational and compassionate approaches to drug use, drug policy and human rights, while also standing out for its coverage of tobacco harm reduction. Its closure is a significant loss - particularly at a time when well-funded opponents of tobacco harm reduction continue to thrive.
Harry’s blog 133: Silence is consent
Two tobacco control consultations that demand your attention
I’m sure there are many of you like me who are deeply cynical about public consultations. They often feel like political tick box exercises allowing the issuing authority from local councils to international organisations to say they have ‘consulted with the people’, when in truth they knew exactly what they were going to do from the get-go.
Harry’s Blog 132: “Zyn! Went The Strings Of My Heart” (with apologies to Judy Garland)
FDA approval of 20 nicotine pouch products is another step forward for tobacco harm reduction
The FDA in the U.S. has granted marketing authorisation for Zyn nicotine pouch products (five variations on mint plus five other flavours in two different strengths).
In its letter to PMI (who own Zyn manufacturers Swedish Match), the FDA wrote:
Based on our review of your MRTPAs [Modified Risk Tobacco Applications] we determined that the proposed modified risk tobacco products, …as actually used by consumers would significantly reduce harm and the risk of tobacco-related disease to individual tobacco users and benefit the health of the population as a whole, taking into account both users of tobacco products and persons who do not currently use tobacco products. Therefore, we authorize marketing of the tobacco products as modified risk tobacco products with the following modified risk information – “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis”.